SCHEMBL623197

SCHEMBL623197

O=C(c1csc(C(F)(F)F)n1)N1CCN(c2cc(OCC(F)(F)F)ncn2)CC1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACACB O00763 1/20 0.39
HTT P42858 2/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
CCKAR P32238 1/20 0.37
RAB9A P51151 1/20 0.37
IRAK4 Q9NWZ3 1/20 0.36
KCNK3 O14649 1/20 0.35
KCNK9 Q9NPC2 1/20 0.35
MAPT P10636 1/20 0.35
HRH4 Q9H3N8 1/20 0.35
SCN9A Q15858 3/20 0.35
RAF1 P04049 1/20 0.34
BRAF P15056 1/20 0.34
MEN1 O00255 2/20 0.34
KMT2A Q03164 2/20 0.34
ELOVL1 Q9BW60 2/20 0.34
CYP1A2 P05177 1/20 0.34
CYP2C9 P11712 1/20 0.34
CYP2C19 P33261 1/20 0.34
ALDH1A1 P00352 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL624375 0.89 HRH3 (0.37) ACACBHTTL3MBTL1IRAK4MAPT
SCHEMBL624123 0.85 PTGDR2 (0.43) ACACBHTTL3MBTL1CCKARRAB9A
SCHEMBL624238 0.83 L3MBTL1 (0.44) HTTL3MBTL1CCKARRAB9ASCN9A
SCHEMBL623298 0.80 PKM (0.43) ACACBHTTL3MBTL1CCKARRAB9A
SCHEMBL623262 0.78 ACACB (0.40) ACACBHTTL3MBTL1CCKARRAB9A
SCHEMBL623899 0.78 PTK2 (0.51) ACACBHTTL3MBTL1CCKARRAB9A
SCHEMBL623245 0.78 TSHR (0.53) CCKARRAB9ASCN9AMEN1KMT2A
SCHEMBL624371 0.76 KCNK3 (0.44) ACACBHTTL3MBTL1CCKARRAB9A
SCHEMBL624181 0.76 CCKAR (0.43) ACACBHTTL3MBTL1CCKARRAB9A
SCHEMBL623698 0.75 P2RY12 (0.45) CCKARRAB9AMEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8999974-B2 Acyl piperazine derivatives as TTX-S blockers RAQUALIA PHARMA INC. (JP) 2015-04-07 US claimed
US-20130150356-A1 Acyl Piperazine Derivatives as TTX-S Blockers RAQUALIA PHARMA INC. (JP) 2013-06-13 US claimed
WO-2012020567-A1 ACYL PIPERAZINE DERIVATIVES AS TTX-S BLOCKERS RAQUALIA PHARMA INC. (JP) 2012-02-16 WO claimed
US-8999974-B2 Acyl piperazine derivatives as TTX-S blockers RAQUALIA PHARMA INC. (JP) 2015-04-07 US disclosed
US-8999974-B2 Acyl piperazine derivatives as TTX-S blockers RAQUALIA PHARMA INC. (JP) 2015-04-07 US disclosed
US-8999974-B2 Acyl piperazine derivatives as TTX-S blockers RAQUALIA PHARMA INC. (JP) 2015-04-07 US disclosed
US-20130150356-A1 Acyl Piperazine Derivatives as TTX-S Blockers RAQUALIA PHARMA INC. (JP) 2013-06-13 US disclosed
WO-2012020567-A1 ACYL PIPERAZINE DERIVATIVES AS TTX-S BLOCKERS RAQUALIA PHARMA INC. (JP) 2012-02-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130150356-A1 Acyl Piperazine Derivatives as TTX-S Blockers SCN5A, SCN2A, CACNA1G ACACB 544/4885HTT 362/4885L3MBTL1 2801/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.